Elanco Animal Health Incorporated — News

Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people.

prnewswire.com - 2026-07-31 07:32:00

On July 29, 2026, Elanco Animal Health Inc (ELAN) shares rose 3.4% to $26.39, continuing a positive trend in the stock's price performance. Over the past year,

gurufocus.com - 2026-07-29 20:23:00

Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-29 11:06:13

California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 4.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,209 shares of the company's stock after selling 35,888 shares during the period. California Public

defenseworld.net - 2026-07-23 03:42:01

Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-22 13:02:10

Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i Newly Published Data Found Credelio Quattro: Faster 2 Tick 1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i  Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off.

prnewswire.com - 2026-07-22 06:27:00

Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health Incorporated (NYSE: ELAN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,871,561 shares of the company's stock, valued at approximately $66,390,000. Allspring Global Investments Holdings LLC owned 0.58%

defenseworld.net - 2026-07-18 03:11:13

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-15 13:10:25

INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

prnewswire.com - 2026-07-08 08:00:00

Investors need to pay close attention to ELAN stock based on the movements in the options market lately.

zacks.com - 2026-06-30 13:40:22

New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector.

prnewswire.com - 2026-06-18 07:26:00

TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini , ii , iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.

prnewswire.com - 2026-06-15 08:47:00

Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.

youtube.com - 2026-06-04 19:23:21

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States  New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi  New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood  Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae  INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i  The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii  "New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods," said Jeff Simmons, President and CEO, Elanco Animal Health.

prnewswire.com - 2026-06-04 06:26:00

On CNBC's “Mad Money Lightning Round,” Jim Cramer said about Zoetis Inc (NYSE:ZTS) that he feels "something not well there."

benzinga.com - 2026-06-03 08:05:12

INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.

prnewswire.com - 2026-06-03 07:26:00

Elanco Animal Health Incorporated (ELAN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

seekingalpha.com - 2026-06-02 18:11:51

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

seekingalpha.com - 2026-05-27 18:27:08

On May 20, 2026, Elanco Animal Health Inc (ELAN) shares rose 5.3% today, closing at $20.85. This increase comes after a challenging month, where shares have dec

gurufocus.com - 2026-05-20 19:25:00

Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours and is given as an in-clinic injection Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours.

prnewswire.com - 2026-05-18 07:27:00

On May 15, 2026, Elanco Animal Health Inc (ELAN) shares fell 8.2% today, bringing the current price to $19.96. The stock has experienced considerable volatility

gurufocus.com - 2026-05-15 21:00:00

INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m.

prnewswire.com - 2026-05-14 08:00:00

Elanco Animal Health NYSE: ELAN raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerating demand for new products and continued debt reduction.

marketbeat.com - 2026-05-10 03:10:41

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 17:41:14

Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #elanco #animalhealth #jeffsimmons #screwworm #outbreak #health #animals #livestock #agriculture #farming #preparedness #biosecurity #veterinary #disease

youtube.com - 2026-05-06 16:16:29

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) are trading higher on Wednesday, following a recent announcement regarding the approval of its products, Negasunt Powder and Tanidil, which received emergency use authorization.

benzinga.com - 2026-05-06 14:33:15

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago.

zacks.com - 2026-05-06 08:45:42

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of $204 million Adjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5% Reported EPS of $0.11, Adjusted EPS of $0.40 Net leverage ratio of 3.5x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.2 billion Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint Improving year-end net leverage ratio target to 3.0x to 3.2x Adjusted EBITDA INDIANAPOLIS, May 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2026, provided guidance for the second quarter of 2026, and updated guidance for the full year 2026. "Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco.

prnewswire.com - 2026-05-06 06:27:00